Plasma growth hormone and prolactin response to dopaminergic GABA mimetic and cholinergic stimulation in Huntington's disease

R. Durso, C. A. Tamminga, A. Denaro, S. Ruggeri, T. N. Chase

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We studied the acute effects of pharmacologic stimulation of neurotransmitter systems implicated in growth hormone and prolactin regulation in eight patients with Huntington's disease and matched control subjects. Both apomorphine, a dopamine agonist, and muscimol, a GABA agonist, produced an exaggerated rise in plasma growth hormone levels in the Huntington patients. Neither the growth hormone response to a muscarinic agonist, arecoline, nor the prolactin response to any of these drugs differed in the patients and controls. Loss of somatostatin activity in the hypothalamic-pituitary axis in Huntington's disease could acount for these endocrinologic changes.

Original languageEnglish (US)
Pages (from-to)1229-1232
Number of pages4
JournalNeurology
Volume33
Issue number9
StatePublished - 1983

Fingerprint

Huntington Disease
Prolactin
gamma-Aminobutyric Acid
Cholinergic Agents
Growth Hormone
Arecoline
GABA Agonists
Muscarinic Agonists
Muscimol
Apomorphine
Dopamine Agonists
Somatostatin
Neurotransmitter Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Plasma growth hormone and prolactin response to dopaminergic GABA mimetic and cholinergic stimulation in Huntington's disease. / Durso, R.; Tamminga, C. A.; Denaro, A.; Ruggeri, S.; Chase, T. N.

In: Neurology, Vol. 33, No. 9, 1983, p. 1229-1232.

Research output: Contribution to journalArticle

@article{4c62f8c0475d46249ae17c81c0389600,
title = "Plasma growth hormone and prolactin response to dopaminergic GABA mimetic and cholinergic stimulation in Huntington's disease",
abstract = "We studied the acute effects of pharmacologic stimulation of neurotransmitter systems implicated in growth hormone and prolactin regulation in eight patients with Huntington's disease and matched control subjects. Both apomorphine, a dopamine agonist, and muscimol, a GABA agonist, produced an exaggerated rise in plasma growth hormone levels in the Huntington patients. Neither the growth hormone response to a muscarinic agonist, arecoline, nor the prolactin response to any of these drugs differed in the patients and controls. Loss of somatostatin activity in the hypothalamic-pituitary axis in Huntington's disease could acount for these endocrinologic changes.",
author = "R. Durso and Tamminga, {C. A.} and A. Denaro and S. Ruggeri and Chase, {T. N.}",
year = "1983",
language = "English (US)",
volume = "33",
pages = "1229--1232",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Plasma growth hormone and prolactin response to dopaminergic GABA mimetic and cholinergic stimulation in Huntington's disease

AU - Durso, R.

AU - Tamminga, C. A.

AU - Denaro, A.

AU - Ruggeri, S.

AU - Chase, T. N.

PY - 1983

Y1 - 1983

N2 - We studied the acute effects of pharmacologic stimulation of neurotransmitter systems implicated in growth hormone and prolactin regulation in eight patients with Huntington's disease and matched control subjects. Both apomorphine, a dopamine agonist, and muscimol, a GABA agonist, produced an exaggerated rise in plasma growth hormone levels in the Huntington patients. Neither the growth hormone response to a muscarinic agonist, arecoline, nor the prolactin response to any of these drugs differed in the patients and controls. Loss of somatostatin activity in the hypothalamic-pituitary axis in Huntington's disease could acount for these endocrinologic changes.

AB - We studied the acute effects of pharmacologic stimulation of neurotransmitter systems implicated in growth hormone and prolactin regulation in eight patients with Huntington's disease and matched control subjects. Both apomorphine, a dopamine agonist, and muscimol, a GABA agonist, produced an exaggerated rise in plasma growth hormone levels in the Huntington patients. Neither the growth hormone response to a muscarinic agonist, arecoline, nor the prolactin response to any of these drugs differed in the patients and controls. Loss of somatostatin activity in the hypothalamic-pituitary axis in Huntington's disease could acount for these endocrinologic changes.

UR - http://www.scopus.com/inward/record.url?scp=0020514682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020514682&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 1229

EP - 1232

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -